Buzz can make or break celebrities’ careers – so what about investors’ portfolios? Though this is a risky path to tread, buzz can talk stocks up or down – and a savvy investor stays on top of the buzz generated by Wall Street.

Goldman Sachs, for example, is getting buzz as a company to buy on the dip. The Enron scandal has wreaked havoc on the market, and on financial services in particular, but some market pros are convinced that Goldman will rise about the Enron taint.

And that’s good news if you want to buy or up a stake in it, said Mark Petrie, vice president of research at Hokanson Capital Management.

Speaking of Goldman and his other mention, Bank of New York, he said: “These are high-quality companies, and as a result of all this fear, we think an opportunity was created.”

Not everyone agrees. “That’s if you assume that Enron is the beginning and the end” of accounting problems, said Martin Weiss, author of “The Ultimate Safe Money Guide.” “I think it’s widely known, but not necessarily widely admitted, that the practices Enron used are far more widespread than anyone imagined,” he said.

In other words, tread carefully.

Or, just stay away from companies with fancy accounting.

Pharmaceutical giant Pfizer is a top pick for Joseph Battipaglia, chairman of the investment policy committee at Gruntal & Co. This company, he said, has “digested its acquisition of Warner Lambert, and has a full pipeline of new product that’s going to be in front of the FDA relatively soon.”

After watching Pfizer’s stock stagnate for about a year, he thinks it’s poised to move higher. And its balance sheet is very straightforward.

Tyco, which shocked Wall Street with an about-face plan to split itself into four entities, is an unlikely favorite of Bernard Beal, CEO of M.R. Beal & Co. He called Tyco “basically a fundamentally sound company” that’s suffering from Enronitis. “It looks like a hell of an opportunity to me,” he said late last week.

More off the beaten track is Cannondale, a Connecticut-based bicycle company. Cannondale’s stock hit a high of $22.94 back in 1998, and it’s now closer to $4. But, it’s been diversifying, and “We just put a “buy” on it,” said Francois Parenteau, of Parenteau Research.

“We believe they will be very successful in carving their own niche in the dirt bike and ATV market.” He said ATV sales are expected to quadruple in the next few years, and that Cannondale could be a takeover target.

If there’s a buzzworthy sector, it just might be biotech. “Biotech is getting hot,” said Beal, likening it to the tech sector of the 1990s -hopefully without the crash and burn. In particular, Beal likes Martek Biosciences, whose nutritional additive for infant formula received a favorable review by the FDA.

“I think it’s an up-and-comer,” Beal said. “I see it as a stock that could go to the mid-$40s.”

And Parenteau gave a thumbs up to little-known Senesco Technologies. The New Jersey-based biotech company is developing technology designed to delay senescence in fresh produce and which Parenteau thinks might one day be used to fight cancerous cells.

Psssst! Have you heard about these?

Believe it or not, there are some stocks out there worth checking out. Here’s a list of what some Wall Street pros predict could be the next big thing:

Company Friday close Buzz

Goldman Sachs $82.76, -$2.35 Jittery investors have knocked it down, giving others a chance to buy on the dip.

Pfizer $41.11, +0.31 New products in the pipeline could aid its growth.

Tyco $27.90, +1.15 Enronitis has this giant trading at an attractive price.

Cannondale $4.05, +0.06 If this bike company is onto something with its all-terrain vehicles, it could be bought up a few years down the road.

Martek Biosciences $28.25, -0.10 The FDA liked its nutritional additive for infant formula, and it looks like a lot of clients will, too.

Senesco Technologies $2.50, +0.07 It says its work could revolutionize agriculture.